Keywords: roche/aspreva, cellcept, enters, ln, trial, canada, aspreva
Roche/Aspreva's CellCept enters LN trial
Article | 08 August 2005
Canada's Aspreva Pharmaceuticals has begun patient dosing in a pivotal Phase III clinical study evaluating CellCept (mycophenolate mofetil) for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
